Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Skuldtech Identifies New Predictive Markers for Pancreatic Cancer Survival

Published: Thursday, January 31, 2013
Last Updated: Wednesday, January 30, 2013
Bookmark and Share
The companion diagnostic developed by Skuldtech from these biomarkers will make it possible to identify patients most likely to benefit from this new treatment.

Skuldtech has announced that it has successfully used its technological platform to identify new biomarkers during a phase III clinical trial. This discovery made it possible to file a marketing authorization application with the regulatory authorities.

These survival markers were identified during a clinical study, whose purpose was to evaluate the therapeutic efficiency of a new treatment combining AB Science's masitinib and gemcitabine, compared to the current standard pancreatic cancer treatment of gemcitabine only.

Patents have been filed to protect the markers, which are also associated with the masitinib marketing authorization application already filed with regulatory authorities by AB Science.

Based on its technological approach associating gene sequencing with its proprietary bioinformatic tools and gene profiling studies (transcriptome) on blood samples, Skuldtech has identified several sets of blood biomarkers associated with the different groups of patients treated in this phase III clinical trial.

To reach this objective, the first part of the protocol was to collect a blood sample from each patient before treatment, establish its transcriptome and associate it with the patient's clinical progress.

Then significant bioinformatic and biostatistical processing enabled the isolation of biological markers associated with each patient group, with patients grouped according to their overall survival.

These biomarkers will be used for developing future diagnostics that will help choose the treatment and establish clinical prognostics for patients.

"To the best of our knowledge, this is the first time that new biological markers have been discovered during a phase III clinical trial. These markers are both specific to the drug being developed and associated with positive patient response," said Didier Ritter, CEO, Skuldtech.

"This research confirms the quality of our technological approach based on transcriptome analysis performed by gene sequencing combined with our proprietary bioinformatic tools and our genomic-level knowledge of blood," said David Piquemal, scientific director at Skuldtech. "This will make our technology highly attractive for pharmaceutical companies interested in seeing their phase III clinical trials succeed."

Based on the same technological approach, Skuldtech also filed two new patents in 2012.

The first, filed in February, is related to predictive blood markers for four-year survival in patients with Chronic Myelomonocytic Leukemia (CMML).

The second, filed in September, is related to predictive blood markers for an inflammatory joint disease.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Chi-Med Initiates Sulfatinib Phase III Registration Study
Company has initiated SANET-p, a Phase III registration trial of sulfatinib with pancreatic neuroendocrine tumors (“NETs”).
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!